Rick E. Winningham, MBA
Rick E. Winningham has served as chairman of the board of directors of Theravance Biopharma, Inc., a diversified biopharmaceutical company since July 2013. He has served as chief executive officer since its spin-off from Innoviva, Inc. in June 2014. From October 2001 to August 2014, Mr. Winningham served as chief executive officer of Innoviva, Inc., where he also served as chairman of the board of directors from April 2010 to October 2014. From 1997 to 2001, he served as president, Bristol-Myers Squibb Oncology/Immunology/Oncology Therapeutics Network (OTN) and also as president of global marketing from 2000 to 2001. In addition to operating responsibility for U.S. Oncology/Immunology/OTN at Bristol Myers Squibb, Mr. Winningham also had full responsibility for global marketing in the cardiovascular, infectious disease, immunology, oncology/metabolics and GU/GI/neuroscience therapeutic areas. Over a 15-year period beginning in 1986 with BMS and its predecessor, Bristol Myers, Mr. Winningham held various U.S. and global management positions.
Mr. Winningham is a member of Biotechnology Industry Organization’s board of directors and serves on the Health Section Governing Board Standing Committee on Reimbursement. Mr. Winningham served as a director on the board of directors of the California Healthcare Institute (CHI) from November 2011 to March 2015. He was elected chairman of CHI in January 2014, a position he held until CHI merged with Baybio to become the California Life Sciences Association (CLSA) in March 2015. Mr. Winningham is on the board of CLSA, and served as its chairman from March 2015 to November 2015. He is a member of the board of directors of Jazz Pharmaceuticals plc, and served as a member of the board of directors of OncoMed Pharmaceuticals, Inc. from June 2015 until April 2019. Mr. Winningham holds an M.B.A. from Texas Christian University and a bachelor’s degree from Southern Illinois University.